Oxymetazoline (Nostrilla®) Nasal Decongestant
October 24, 2011
Insight Pharmaceuticals issued a nationwide, voluntary recall of one lot of oxymetazoline nasal spray (Nostrilla®) due to possible contamination with Burkholderia cepacia. The affected product was sold through retail stores and pharmacies. The recalled product can be found under the name Nostrilla Nasal Decongestant (lot #11G075, UPC Code 6373673005, expiration date 05/2014).
Burkholderia cepacia can cause serious infection in immunocompromised patients or individuals with chronic lung disease. Infection is unlikely in healthy individuals. Currently, no illnesses have been reported in connection with this product’s use.
Consumers and healthcare professionals should stop using the affected product immediately. Return the affected product for refund to the place of purchase, or by calling Insight Pharmaceuticals at 1-877-546-9059 weekdays from 9:00 AM to 5:00 PM Eastern Standard Time. Report any adverse events to the FDA’s Medwatch program.
Additional information is available at the following links:
- MedWatch Alert:
- Company Press Release:
October 24, 2011; University of Utah, Drug Information Service. Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT.